Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

NCT07309276 is registered in ClinicalTrials.gov with Shanghai Junshi Bioscience Co., Ltd. as lead sponsor.

NCT NCT07309276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07309276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer
Lead sponsor
Shanghai Junshi Bioscience Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
January 23, 2026
Completion date
November 11, 2028
Enrollment
864 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lung cancer